{
    "2019-02-19": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review",
                "features": {
                    "keywords": [
                        "Roche",
                        "BLA",
                        "Lymphoma",
                        "Drug",
                        "Priority Review"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "2 Pharma Stocks in the Middle of an Oncology Sales Explosion",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stocks",
                        "Oncology",
                        "Sales",
                        "Explosion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "AbbVie stock up 0.2% after FDA grants upadacitinib priority review status",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "stock",
                        "up",
                        "FDA",
                        "upadacitinib",
                        "priority",
                        "review",
                        "status"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "New Drug Application",
                        "Priority Review",
                        "U.S. FDA",
                        "Upadacitinib",
                        "Rheumatoid Arthritis"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}